Objective-Stimulation of cardiac α 1A -adrenergic receptors (α 1A -AR) has been proposed for treatment of heart failure, since it increases myocardial contractility. We investigated a different mechanism, induction of angiogenesis. Approach and Results-Four to 6 weeks after permanent coronary artery occlusion, transgenic rats with cardiomyocytespecific α 1A -adrenergic receptor overexpression had less remodeling than their nontransgenic littermates, with less fibrosis, hypertrophy and lung weight, and preserved left ventricular ejection fraction and wall stress (all P<0.05 ; P<0.05), which is consistent with angiogenesis, as reflected by a 20% increase in capillary density in the zone adjacent to the infarct. The question arose, how does transgenic overexpression of a gene in cardiomyocytes induce angiogenesis? We identified a paracrine mechanism, whereby vascular endothelial growth factor-A mRNA and protein were increased in isolated transgenic cardiomyocytes and also by nontransgenic littermate cardiomyocytes treated with an α 1A -agonist, resulting in angiogenesis. Conditioned medium from cultured cardiomyocytes treated with an α 1A agonist enhanced human umbilical vein endothelial cell tubule formation, which was blocked by an anti-vascular endothelial growth factor-A antibody. Moreover, improved cardiac function, blood flow, and increased capillary density after chronic coronary artery occlusion in transgenic rats were blocked by either a mitogen ERK kinase (MEK) or a vascular endothelial growth factor-A inhibitor. Conclusion-Cardiomyocyte-specific overexpression of the α 1A -adrenergic receptors resulted in enhanced MEK-dependent cardiomyocyte vascular endothelial growth factor-A expression, which stimulates angiogenesis via a paracrine mechanism involving heterocellular cardiomyocyte/endothelial cell signaling, protecting against remodeling and heart failure after chronic coronary artery occlusion.
C ardiac-specific α 1A -adrenergic receptor (α 1A -AR) stimulation has been proposed as a therapeutic strategy for heart failure, [1] [2] [3] [4] [5] as it increases myocardial contractility, 6, 7 and blockade of the α 1 -AR exacerbates heart failure. 2, 3 We investigated a different mechanism, namely that cardiomyocyte-specific overexpression of the α 1A -AR induces angiogenesis through a paracrine mechanism, which could be therapeutically beneficial for heart failure, particularly that due to chronic myocardial infarction (MI). This is because, in the presence of permanent coronary artery occlusion (CAO), even cardioprotective interventions are destined to fail as they do not increase blood flow distal to the CAO, even to that observed in hibernating myocardium. 8, 9 This is required to limit ischemic damage to the myocardium. In fact, despite the hundreds, if not thousands, of studies identifying molecular pathways protecting the heart, there has been little clinical translation of these findings, and even approaches to enhance myocardial regeneration have met with uneven success. 10 In the permanent absence of blood flow to the ischemic heart and in the absence of preformed collateral channels, almost any intervention is destined to fail. Although several transgenic models have shown cardioprotection in the setting of ischemia/reperfusion, [11] [12] [13] the key is that in reperfusion models, blood flow is restored after a relatively short duration of ischemia, generally from 15 minutes to an hour.
For these reasons, we investigated here whether α 1A -AR overexpression also limits cardiac remodeling after chronic MI resulting from permanent CAO. Specifically, we examined the effects of permanent CAO on the development of remodeling and heart failure in a rat model with 40-fold cardiomyocyte overexpression of the α 1A -AR. Our hypothesis was that if we observed protection from remodeling after 4 weeks of permanent CAO in the transgenic rats, then there must have been some sustained blood flow to the ischemic myocardium, resulting in preservation of left ventricular (LV) ejection fraction and wall stress ( Figure 1 ). Indeed, we did observe that the transgenic α 1A -AR rat heart was protected from remodeling after permanent CAO, and because, unlike the dog and hamster, 14 the rat has few preformed collateral vessels, we also examined the extent to which protection against remodeling is mediated by angiogenesis. Accordingly, we measured coronary blood flow to the ischemic zone and quantified the percentage of viable myocardium within this zone, as well as the development of newly formed coronary vessels and Ki67-positive myocytes. Because overexpression of the α 1A -AR was restricted to cardiomyocytes, we then determined the mechanism underlying neoangiogenesis in the transgenic hearts. Given that microarray studies, verified by quantitative polymerase chain reaction, identified vascular endothelial growth factor-A (VEGF-A) as the sole angiogenesis gene upregulated in transgenic myocytes, we focused on this factor and also examined mitogen ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) signaling, which has been found to be activated with α 1A -AR stimulation [15] [16] [17] and to induce VEGF-A mediated angiogenesis.
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Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Attenuated Cardiac Remodeling in Transgenic Rats After Chronic MI
At 4 to 6 weeks post MI, compared with nontransgenic littermates (NTLs), transgenic rats showed significantly less fibrotic tissue deposition in the areas adjacent (25% less) and remote (33% less) to the ischemic zone ( Figure 2A ). Compared with baseline, the amount of cellular hypertrophy post MI was significantly less in the transgenic group in both the adjacent (573±14 mm 2 ) and remote zones (485±34 mm 2 ) versus those seen in the NTLs (652±24 mm 2 in the adjacent zone and 582±18 mm 2 in the remote zone; P<0.05; Figure 2B ). Consistent with these findings, the ratio of LV weight/tibial length was reduced by 16% in transgenic rats compared with NTLs ( Figure 2C ; P<0.05) and the ratio of lung weight/tibial length was also lower in transgenic Figure 2E ). This reduction in infarct size was accompanied by increased viable tissue within the ischemic zone in transgenic rats (12±1.0% versus 7.9±1.2% in NTLs; P<0.05; Figure 2D and 2E) and was also accompanied by increased Ki67-positive myocytes in the ischemic zone ( Figure 2E ). LV ejection fraction fell to 38% in NTLs, but it was significantly preserved at 63% in transgenic rats ( Figure 1B ; Table 1 ). The low LV ejection fraction in NTLs 4 to 6 weeks after CAO (38%) is at a level found in other studies of rats with heart failure, and in this study, it was supported by the increases in LV weight/tibial length and lung weight/tibial length in NTLs, indicative of heart failure. Mortality, by χ 2 analysis, with 4 to 6 weeks CAO, was significantly reduced, P<0.05, in transgenic (18%) versus NTL (47%) rats.
Increased Angiogenesis in Transgenic Rats With Upregulation of VEGF-A
Myocardial blood flow was studied with microspheres injected at 1 day, 1 week, 2 weeks, and 4 weeks post MI. During the 4-week period of permanent CAO, both groups showed a gradual recovery of blood flow within the ischemic zone. However, the rate of recovery was significantly faster and greater in transgenic rats when compared with their NTLs ( Figure 3A) . At 4 weeks post MI, the blood flow in the central ischemic, adjacent, and remote zones was consistently higher in TG group compared with NTL rats (P<0.05; Figure 3B ).
Capillary density was increased by 21% in the zone adjacent to the infarct in transgenic rats compared with NTLs at 4 to 6 weeks after MI (P<0.05; Figure 3C ). This was consistent with the finding of more viable tissue within the ischemic zone in transgenic rats ( Figure 2E ), secondary to collateral blood flow through angiogenesis.
Determination of angiogenic genes using microarray analysis revealed 6 upregulated angiogenesis-related genes in cardiomyocytes of transgenic rats. Of the 6 genes, only VEGF-A mRNA was validated by quantitative polymerase chain reaction to be significantly increased compared with NTLs ( Figure  3D ). In addition, we found a 3-fold increase in VEGF-A protein levels in transgenic mouse cardiomyocytes compared with NTLs (P<0.05; Figure 4A ).
Activation of the α 1A -AR in CardiomyocytesInduced Angiogenesis via a Paracrine Mechanism
In isolated mouse cardiomyocytes, VEGF-A expression was found to be upregulated at both the protein and mRNA levels . A, Fibrosis, quantified using picrosirius red staining, was decreased in TG. B, Myocyte size, determined using WGA (rhodamine-conjugated wheat germ agglutinin) fluorescent staining, was decreased in the zones bordering and remote to the ischemic area. C, Left ventricular (LV) weight/tibial length (TL) ratio was decreased in TG rats. D, Trichrome staining of LV rings (top) and transverse sections (bottom) of both NTL and TG hearts after chronic myocardial infarction demonstrates reduced scar size and fibrosis in the TG heart, as well as evidence of viable myocardium within the scar. E, Scar size, presented as the percentage of scar size to LV surface area, was decreased in the TG vs NTL hearts, whereas the amount of viable myocardium within the ischemic zone was increased in TG vs NTL hearts. This was accompanied by increased Ki67-positive myocytes in the ischemic zone in the TG vs NTL hearts. Results are expressed as mean±SEM. n=6 to 8 per group; *P<0.05 vs NTL. MI indicates myocardial infarction.
in transgenic mouse cardiomyocytes compared with those in NTLs ( Figure 4A and 4B). VEGF-A levels also increased significantly after stimulation of NTL cardiomyocytes with α 1A -AR agonist, A61603 (25 nmol/L; Figure 4A and 4B). A61603-mediated upregulation of VEGF-A mRNA was abolished by pretreatment of cardiomyocytes with the α 1A -AR antagonist, prazosin (1 µmol/L; Figure 4B ), indicating that the upregulation of VEGF-A is mediated by the α 1A -AR.
To evaluate the underlying cellular mechanism of the α 1A -AR-mediated angiogenic effect, we used a Matrigel culture system using human umbilical vein endothelial cells. Tubule formation was increased after treating human umbilical vein endothelial cells with conditioned medium collected either from cultured transgenic cardiomyocytes or from A61603-treated NTL cardiomyocytes, but it was completely abolished by pretreatment with an anti-VEGF-A antibody ( Figure 4C and 4D) but not by pretreatment with control IgG (data not shown). This suggests that the growth factor, VEGF-A, is required for endothelial cell growth and organization into tubules, after its release from cardiomyocytes on activation or with overexpression of the α 1A -AR. Thus, the α 1A -AR seems to program an angiogenic response within the myocardium that enhances endothelial cell organization through a paracrine mechanism involving heterocellular signaling.
Diminished Myocardial Remodeling in Transgenic Rats Was Abolished by Inhibition of the MEK-VEGF-A Pathway
U0126, a MEK inhibitor, or SU5416, a VEGF receptor inhibitor, was administered throughout the 4 weeks post MI period in both NTLs and transgenic rats. Table 2 compares the effects of the MEK and VEGF receptor inhibitors in NTLs and transgenic rats with those observed in NTLs and transgenic rats given only vehicle. At 4 weeks post MI, the preserved cardiac function and attenuated remodeling observed in vehicle-treated transgenic rats, when compared with their vehicle-treated NTLs, were abolished after treatment with either inhibitor. Thus, with inhibitor treatment, cardiac function, reflected by ejection fraction, and LV wall stress were now similar in the transgenic animals and their NTLs (Table 2) . Also, scar size was not significantly different between U0126-or SU5416-treated NTL and transgenic hearts at 4 weeks post MI ( Figure  5A ). Compared with vehicle-treated transgenic hearts post showing that recovery of flow was significantly faster and of greater magnitude in transgenic (TG) vs nontransgenic littermate (NTL) rat hearts at the times indicated (n=4-6; P<0.05). B, Coronary blood flow was increased in central ischemic, adjacent to ischemic and remote to ischemic zones of the heart. C, Capillary density, normalized to NTLs, was increased in TG hearts at 4 to 6 weeks post CAO in the zone adjacent to the scar. D, Upregulation of angiogenic genes expressed in TG and NTL cardiomyocytes was determined by microarray analysis. The mRNA expression was further verified using quantitative polymerase chain reaction. The significant increase in vascular endothelial growth factor-A (VEGF-A) expression in TG hearts was verified. Results are expressed as mean±SEM; n=4 to 8; *P<0.05 vs NTL. Angpt-2 indicates angiopoietin-2; cTGF, connective tissue growth factor; FGF2, fibroblast growth factor-2; FGF6, fibroblast growth factor-6; Hbegf, heparin-binding epidermal growth factor-like growth factor; and MI, myocardial infarction.
MI, transgenic hearts treated with U0126 or SU5416 did not show an increase in myocardial blood flow, suggesting that treatment with either inhibitor caused regression of collateral vessels ( Figure 5B ). Capillary density within the adjacent zone was no longer increased in transgenic rats treated with either inhibitor but was similar among the inhibitor-treated NTL and transgenic groups ( Figure 5C ). In A61603-treated NTL mouse cardiomyocytes, pretreatment with U0126 markedly reduced VEGF-A mRNA and protein levels ( Figure 5D ).
Discussion
In the present investigation, we demonstrated that overexpression of α 1A -AR in cardiomyocytes protected the heart from the adverse effects of remodeling and heart failure that occurs after permanent CAO (Figure 1 ). In the rat model of heart failure induced by permanent CAO, others have reported that LV ejection fraction falls to levels of 40% to 45% after heart failure develops [19] [20] [21] and have used this model of heart failure to devise current heart failure therapy in patients. These values are similar to those we observed with CAO of NTLs in this study, where LV ejection fraction fell to 38%, 4 to 6 weeks after permanent CAO. In contrast, LV function was better preserved with less remodeling after CAO, in terms of fibrosis, myocyte hypertrophy, LV weight/tibial length and lung weight/tibial length, and scar size, in the transgenic rats. Although cardiac α 1A -AR stimulation has been proposed previously for the treatment of heart failure on the basis of its increased inotropic properties, and because α 1A -AR blockade exerts an adverse effect in heart failure, [1] [2] [3] the results of the current investigation provide an additional novel mechanism that mediates α 1A -AR protection against the remodeling and the development of heart failure that occurs after permanent CAO, that is, α 1A -AR-stimulated angiogenesis.
Because with complete CAO, it is difficult for modulators of apoptosis or preconditioning to work without blood flow to keep the tissue alive, we concluded that the chronic protection must have ensued because of angiogenesis in the transgenic rats. This provided collateral blood flow to the central ischemic and adjacent zones after CAO and restored blood flow to the ischemic myocardium, resulting in less cell death with more viable tissue within the ischemic zone and within the central infarct area. We documented the recovery of myocardial blood flow in the central ischemic zone and the zone adjacent to the infarct using the microsphere method, which is one of the only ways to measure regional myocardial blood flow after permanent CAO. It is important to appreciate that additional salvage of myocardium can come later in the process because of the positive effects of remodeling, resulting in reduced LV wall stress and myocardial oxygen demand. This is the first report of the α 1A -AR being linked to angiogenesis. Although norepinephrine was found to induce VEGF-A expression and angiogenesis, 22 the adrenergic receptor involved was not determined. There is evidence that the α-AR can stimulate angiogenesis 23 ; however, our studies indicate for the first time that in the heart, the α 1A -AR/MEK/VEGF-A pathway seems to be the mediator of angiogenesis via heterocellular myocyte/endothelial cell signaling. Elucidation of this pathway was greatly aided by the availability of the transgenic rat model, which is more amenable to detailed physiological investigations than the mouse.
Involvement of the α 1A -AR/MEK/VEGF-A pathway in angiogenesis is evident from the following observations. Firstly, we demonstrated that the transgenic rats with α 1A -AR overexpression had preserved cardiac function with higher ejection fraction and lower LV wall stress than NTLs (Table  1) . Transgenic rats had similar LV systolic pressure with smaller LV chambers and significantly greater wall thickness at systole, and their LV systolic wall stress was markedly lower than that in the NTLs (Table 1) . Reduced wall stress, per se, could have contributed to the cardioprotection because it reduces myocardial oxygen requirements. However, as noted above, this by itself, in the absence of some preservation of blood supply, is not sufficient to protect the heart subjected to 4 weeks of permanent CAO. Secondly, using histological staining, scar size, measured as a percentage of the total myocardium, was markedly smaller in transgenic hearts and was accompanied by more viable tissue and capillaries within the scar and less fibrosis in ischemic and adjacent zones, suggesting that the mechanism of protection involved angiogenesis. The mechanisms mediating adjacent and remote remodeling are complex and likely different. The adjacent zone, which also suffers from some myocardial ischemia, is influenced positively by angiogenesis and improved myocardial perfusion. This is not the case for the remote zone, which never experiences myocardial ischemia. The improvement in the remote zone is due more to the positive effects on remodeling and reduced LV wall stress and myocardial oxygen demand, which protects against further myocyte necrosis and secondary myocyte hypertrophy and fibrosis.
The conclusions from previous work on differences in regulation of α-receptors in endothelial cells and cardiomyocytes are controversial. 23, 24 Some studies have implied that α-receptors on endothelial cells may induce vasodilation, 23, 24 whereas others have suggested vasoconstriction. 25, 26 Studies have found different results on which subtypes of α-receptors are predominant 23, 24 and whether there are differences between regulation of right ventricle versus LV or normal versus heart failure. 27 Although all of these points are interesting and important, they really do not bear on the major findings of this present article.
We found that overexpressed α 1A -receptors in myocytes induced angiogenesis both in vivo and in vitro and that the additional myocardial blood flow was necessary for improved function of the heart after chronic CAO. Previous studies have shown that α-adrenergic receptor inhibition rather than stimulation in brain and hindlimb endothelial cells induced angiogenesis, 28 which is opposite to our results in the heart. To our knowledge, there is no extant evidence showing that overexpression of any α-receptor subtype in the heart can induce angiogenesis, and there are relatively few myocyte-specific transgenic models for any gene that has been shown to protect against permanent CAO by inducing angiogenesis, unless that model also affected angiogenesis directly 29 or through a pathway that induced angiogenesis, for example, elaboration of an associated growth factor. 30 We next determined the angiogenic factor that mediates the increase in blood flow and in capillary density in the α 1A -AR transgenic rat model with permanent CAO. Microarray analysis revealed enhanced expression of 6 angiogenic growth factor genes in transgenic versus NTL cardiomyocytes. However, only enhanced VEGF-A expression in transgenic cardiomyocytes could be verified by quantitative polymerase chain reaction ( Figure 3C ). VEGF-A promotes endothelial proliferation and migration resulting in tubule formation, [31] [32] [33] and as a proangiogenic factor, it is known to be activated by hypoxia and has an important role in angiogenesis and in reducing hypoxic cellular damage. 32, 34 Because the promoter used in the transgenic model was cardiac myocyte specific, there was no overexpression of α 1A -AR in the vessels or endothelial cells, and therefore, we postulated a paracrine mechanism, whereby angiogenesis was induced in the current myocyte-specific transgenic model through a cross talk between the cardiomyocytes and endothelial cells, also known as heterocellular signaling, which has been described for the interaction between one cell type and another in the same organ. [35] [36] [37] [38] Although heterocellular signaling has been described between several cell types, [35] [36] [37] [38] [39] the current investigation focused on cross talk between cardiomyocytes overexpressing the α 1A -AR and endothelial cells to induce angiogenesis. This paracrine mechanism seems to involve transmission of a signal from one cell type to an adjacent cell via the elaboration by the former of a secreted factor-in this case, VEGF-A secretion from cardiomyocytes acting on endothelial cells or vascular smooth muscle cells, to induce angiogenesis as a result of their proliferation and migration. 29, 35, 37, 40, 41 To further confirm the link between α 1A -AR stimulation and VEGF-A secretion, we examined the effects of α 1A -AR agonist stimulation, using A61603, 42 directly on cultured NTL mouse cardiomyocytes. We elected to use cardiomyocytes isolated from mice instead of rats for the mechanistic studies because endogenous α 1A -AR expression in mice is several fold less than rats and is more akin to that in humans. 3 Treatment with A61603 enhanced VEGF-A expression at both the mRNA and protein levels; effects that were blocked by the nonspecific α 1 -AR antagonist, prazosin ( Figure 4B ). In addition, conditioned medium from cultured transgenic myocytes or from A61603-treated NTL myocytes induced vascular tubule formation by human umbilical vein endothelial cells (which do not express endogenous α 1A -AR), significantly more than conditioned medium obtained from cultured untreated NTL cardiomyocytes. These findings support our concept of heterocellular signaling between cardiomyocytes and vascular cells. In keeping with this notion, enhanced myocardial VEGF-A production, observed in response to hypertrophic or ischemic signals, has been shown to activate endothelial cells and to induce angiogenesis. 40, 41 The MEK/ERK pathway has been found to be upregulated in hearts with cardiomyocyte-specific α 1A -AR overexpression 15, 16 and is also activated with in vitro receptor stimulation of cardiomyocytes expressing native levels of the α 1A -AR. 43 In this study, inhibition of the MEK pathway with U0126 abolished the attenuated cardiac remodeling observed after MI in transgenic rats by not only increasing LV wall stress and decreasing LV contractility but also by decreasing capillary density. In agreement with our findings, previous studies have suggested that MEK/ERK signaling is essential for VEGF-regulated endothelial cell proliferation. 18, 44, 45 The MEK/ERK pathway has also been shown to mediate preconditioning in the CAO/reperfusion model. 11 However, as noted above, the molecular mechanism is not effective in the absence of blood flow.
There is another point that needs to be considered. Recently, Ye et al 46 reported that VEGF plays a role in cardiomyocyte differentiation from induced pluripotent stem cells. Although there is substantial evidence that the increases in blood flow are sufficient to explain the preservation of myocytes, it is possible that an effect on cardiomyocyte differentiation contributes. We measured Ki67-positive myocytes and found that there was a significant increase in labeling in the transgenic rats versus NTLs in the ischemic zone, 47 suggesting the induction of new myocytes and preservation of older myocytes. It is difficult to distinguish which is the chicken versus the egg, but it is conceivable that the increased blood flow because of angiogenesis permitted this to occur. Responses of nontransgenic littermates (NTLs) and transgenic (TG) rats to 4 weeks of coronary artery occlusion (CAO) and treatment with vehicle (10% DMSO), the MEK (mitogen ERK kinase) inhibitor, U0126 (400 µg/kg per day), or the vascular endothelial growth factor (VEGF) receptor inhibitor, SU5416 (25 mg/kg per day). A, Scar size was significantly smaller in the vehicle-treated TG vs NTL hearts; a difference that was no longer observed after inhibitor treatment. B, Coronary blood flow in the ischemic zone after 4 weeks of CAO was significantly higher in TG vs NTL hearts, and the increase in the TG hearts was abolished with either U0126 or SU5416 treatment for 4 weeks. C, Capillary density, normalized to NTLs, was increased in the adjacent zone of TG after 4 weeks of CAO, and this increase was abolished with either U0126 or SU5416 treatment for 4 weeks. D, In NTL cardiomyocytes, A61603 increased VEGF-A mRNA and protein levels, and these increases were prevented when the α 1A -adrenergic receptor agonist was combined with U0126. Results are expressed as mean±SEM; n=4 to 6; *P<0.05 vs NTL+vehicle; †P<0.05 vs TG+vehicle; and ‡P<0.05 vs A61603-treated NTL cardiomyocytes.
In summary, the results of this investigation suggest a novel therapeutic target for improved clinical outcomes by limiting post-MI loss of myocardium and, hence, remodeling and heart failure as a result of α 1A -AR-MEK/VEGF-A-mediated angiogenesis, an effect that also protects the function of marginally ischemic myocardium adjacent to the infarct. Protection against remodeling (less fibrosis and myocyte hypertrophy) also protects the nonischemic zone after chronic CAO, a mechanism, unlike the adjacent zone, not dependent on increased blood flow. Another novel finding was that overexpression of cardiomyocytes-specific α 1A -AR was able to induce angiogenesis, a mechanism that might be available for other myocyte proteins and might promote a new line of research in the angiogenesis field. Although cardiac α 1 -AR stimulation has been proposed as a potential treatment for heart failure based on its ability to augment inotropy, 1 this is the first time that the α 1A -AR has been linked to the enhanced expression of a potent proangiogenic factor, VEGF-A, a factor that also induces angiogenesis in response to ischemia. This mechanism improving perfusion to ischemic myocardium changes the paradigm explaining α 1A -AR's salutary action in heart failure, from simply increasing inotropy, which also increases myocardial oxygen consumption, to increasing inotropy while improving perfusion, which protects myocardial oxygen consumption.
